卡瑞利珠单抗联合化疗对老年非小细胞肺癌患者血清细胞角蛋白19片段抗原21-1、基质金属蛋白酶9表达及肿瘤生长转移的影响  

The effect of camrelizumab monoclonal antibody combined with chemotherapy on serum CY211,MMP⁃9expressions and tumor growth and metastasis in elderly patients with non⁃small cell lung cancer

作　　者：吴克林[1] 吴天英[1] 许海 WU Kelin;WU Tianying;XU Hai(Department of Geriatrics,the First People′s Hospital of Jingzhou,Jingzhou 434007,China)

机构地区：[1]荆州市第一人民医院老年医学科,湖北荆州434007 [2]湖北中医药大学黄家湖医院妇科,武汉430070

出　　处：《实用医学杂志》2020年第20期2830-2833,共4页The Journal of Practical Medicine

基　　金：中国博士后科学基金(编号:2013M542498);湖北省自然科学基金(编号:2018CFC808)。

摘　　要：目的观察卡瑞利珠单抗联合化疗对老年非小细胞肺癌(NSCLC)患者血清细胞角蛋白19片段抗原21-1(CY211)、基质金属蛋白酶9(MMP-9)表达及肿瘤生长转移的影响。方法选取2017年1月至2019年10月在本院就诊的老年NSCLC患者120例,随机分为观察组和对照组各60例,对照组给予化疗方案治疗,观察组给予卡瑞利珠单抗联合化疗方案治疗,3个周期后进行疗效评价,并比较两组患者治疗前后血清CY211、MMP-9表达及肿瘤生长转移的变化情况。结果治疗后,观察组总有效率显著高于对照组(P <0.05);两组患者血清CY211、MMP-9、血管内皮生长因子(VEGF)表达水平均较治疗前降低,观察组低于对照组(P <0.05);两组卡氏生存质量(KPS)评分均较治疗前提高,观察组高于对照组(P <0.05)。结论卡瑞利珠单抗联合化疗对老年NSCLC患者疗效显著,可显著降低患者血清CY211、MMP-9、VEGF水平,减少新生血管生成及抑制肿瘤生长转移,提高患者生存质量。Objective To observe the effects of camrelizumab monoclonal antibody combined with chemo⁃therapy on the expressions of cytokeratin 19 fragment antigen 21⁃1(CY211),matrix metalloproteinase⁃9(MMP⁃9)and tumor growth and metastasis in elderly patients with non⁃small cell lung cancer(NSCLC).Methods From January 2017 to October 2019,120 elderly NSCLC patients were randomly divided into observation group and control group,with 60 cases in each group.The control group was treated with chemotherapy,while the observation group was treated with camrelizumab monoclonal antibody combined with chemotherapy.The therapeutic effect was evaluated after 3 cycles,and the changes of serum CY211,MMP⁃9 expressions and tumor growth and metastasis were compared before and after treatment.Results After treatment,the total effective rate of the observation group was significantly higher than that of the control group(P<0.05).The levels of serum CY211,MMP⁃9 and vascular endothelial growth factor(VEGF)in the two groups were lower than those before treatment,and the obser⁃vation group was lower than the control group(P<0.05).The Karnofsky Performance Scale(KPS)score of both groups was higher than that before treatment,and the observation group was higher than the control group(P<0.05).Conclusions Camrelizumab monoclonal antibody combined with chemotherapy has a significant effect on elderly NSCLC patients,which can significantly reduce the levels of serum CY211,MMP⁃9 and VEGF,reduce neovascularization,inhibit tumor growth and metastasis,and improve the quality of life of the patients.

关 键 词：卡瑞利珠单抗 化疗 非小细胞肺癌 细胞角蛋白19片段抗原21-1 基质金属蛋白酶9 生长转移 

分 类 号：R734.2[医药卫生—肿瘤]